Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018 (vol 39, pg 3711, 2022)

被引：0
|
作者：
Liu, Yifei [1 ]
Skup, Martha [1 ]
Yang, Min [1 ]
Qi, Cynthia Z. [1 ]
Wu, Eric Q. [1 ]
机构：
[1] Univ Missouri, Sch Pharm, 1228 Hlth Sci Bldg,2464 Charlotte St, Kansas City, MO 64108 USA
来源：
ADVANCES IN THERAPY | 2022年 / 39卷 / 11期
关键词：
D O I：
10.1007/s12325-022-02255-6
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：5300 / 5300
页数：1
相关论文
共 7 条
  • [1] Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
    Yifei Liu
    Martha Skup
    Min Yang
    Cynthia Z. Qi
    Eric Q. Wu
    Advances in Therapy, 2022, 39 : 3711 - 3734
  • [2] Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
    Liu, Yifei
    Skup, Martha
    Yang, Min
    Qi, Cynthia Z.
    Wu, Eric Q.
    ADVANCES IN THERAPY, 2022, 39 (08) : 3711 - 3734
  • [3] Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
    Yifei Liu
    Martha Skup
    Min Yang
    Cynthia Z. Qi
    Eric Q. Wu
    Advances in Therapy, 2022, 39 : 5300 - 5300
  • [4] Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
    Numan, Syed
    Faccin, Freddy
    ADVANCES IN THERAPY, 2018, 35 (09) : 1295 - 1332
  • [5] Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
    Syed Numan
    Freddy Faccin
    Advances in Therapy, 2018, 35 : 1295 - 1332
  • [6] Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
    Yifei, L.
    Skup, M.
    Yang, M.
    Qi, C.
    Doctor, T.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S334 - S334
  • [7] Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
    Rosembert, D.
    Malaviya, A.
    How, J.
    Tomlison, J.
    Toh, F.
    Roe, M.
    Nightingale, A.
    Garcia-Sueiro, C.
    Herbert, P.
    Jadon, D.
    Norris, P.
    Thomas, J.
    Magsino, J.
    Negoescu, A.
    Raine, T.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S438 - S439
1